Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

University of Miami

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Oligodendroglioma

Glioblastoma Multiforme

H3 K27M

Diffuse Intrinsic Brainstem Glioma

Fibrillary Astrocytomas

DIPG Brain Tumor

Diffuse Intrinsic Pontine Glioma

Anaplastic Astrocytoma

Treatments

Drug: SIACI of cetuximab and bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT05956821

20230032

Details and patient eligibility

About

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

Enrollment

20 estimated patients

Sex

All

Ages

1 to 21 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), fibrillary astrocytomas (FA), pilomyxoid astrocytoma (PXA), oligodendroglioma, or anaplastic mixed oligoastrocytoma (AOA), or radiologically diagnosed diffuse intrinsic brainstem glioma (DIPG)
Must have at least one confirmed and evaluable tumor site
Must have a Karnofsky or Lansky performance status ≥60%.
No chemotherapy for three weeks prior to treatment
Patients must have adequate hematologic reserve with absolute neutrophils≥1000/mm3 and platelets ≥100,000/ mm3
Pre-enrollment chemistry parameters must show: bilirubin<1.5x the institutional upper limit of normal (IUNL); Aspartate Aminotransferase( AST) or Alanine transaminase (ALT)<2.5x IUNL and creatinine<1.5x IUNL
Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5x the IUNL
Growth factor(s): Must not have received within 1 week of entry onto this study
Steroids: Systemic corticosteroid therapy is permissible in patients with Central Nervous System (CNS) tumors for treatment of increased intracranial pressure or symptomatic tumor edema. Patients with CNS tumors who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to study entry.
Patients of reproductive age must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study
Patients or their parents/guardians must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening
Because of known concerns with Avastin and wound healing, craniotomy patients are eligible for the treatment if they have had a craniotomy greater than two weeks prior to Intra-Arterial (IA) therapy. Craniotomy or major procedure after SIACI Avastin therapy should wait 4 weeks. Minor surgeries may be performed after two weeks

Exclusion criteria

Females who are pregnant or lactating
Females of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period. If they do not agree, they will be ineligible for the study
Patients with significant concurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring